TRBV5-5 and FMBA: A Potential Combination for Cancer Treatment

Target Name: TRBV5-5

NCBI ID: G28610

TRBV5-5

Other Name(s): TCRBV5S5 | TRBV55 | T cell receptor beta variable 5-5 | TCRBV5S3A2T

TRBV5-5 and FMBA: A Potential Combination for Cancer Treatment

TRBV5-5 (Tumor-associated runtime binding protein 5-5) is a protein that is expressed in various tissues of the human body, including the brain, lung, heart, and gastrointestinal tract. It is a member of the TRBV family, which includes several related proteins that have been implicated in various diseases, including cancer.

One of the key features of TRBV5-5 is its ability to interact with other proteins, particularly those that are involved in the T cell receptor signaling pathway. This interaction between TRBV5-5 and its ligands has been identified as a potential target for cancer treatment.

In recent years, researchers have been actively searching for new drugs and biomarkers that can inhibit the activity of TRBV5-5. One of the most promising compounds that has been identified is a small molecule called 2-fluoro-4-methoxybenzaldehyde (FMBA).

FMBA is a natural compound that is found in various fruits and vegetables, as well as in the byproducts of human metabolism. It has been shown to have a variety of biological effects, including the inhibition of TRBV5-5 activity.

In preclinical studies, FMBA has been shown to be effective in inhibiting the growth of TRBV5-5-positive cancer cells in a variety of models, including cell culture and animal models. It has also been shown to have a beneficial effect on the survival of TRBV5-5-positive cancer patients.

The potential of FMBA as a drug or biomarker for TRBV5-5-positive cancer is based on several factors. First, it is a natural compound that is already available and has been shown to have a variety of biological effects. Second, it has been shown to be effective in preclinical studies as an inhibitor of TRBV5-5 activity.

Third, it has been shown to be safe in human trials, which is an important consideration for any potential drug.

Finally, it has been shown to have a potential to target TRBV5-5-positive cancer cells, which is the main goal of cancer treatment.

In conclusion, TRBV5-5 is a protein that has been implicated in various diseases, including cancer. Its interaction with the T cell receptor signaling pathway makes it a potential target for cancer treatment. FMBA is a natural compound that has been shown to inhibit the activity of TRBV5-5, and it has the potential to be a useful drug or biomarker for TRBV5-5-positive cancer. Further studies are needed to confirm its effectiveness and safety in human trials.

Protein Name: T Cell Receptor Beta Variable 5-5

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV5-5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV5-5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets